Skip to main content
Livermore
Livermore
ZHEN

Cardiff Oncology, Inc.

CRDF
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001213037

In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.

Holders of 5% or more of CRDF

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cardiff Oncology, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of CRDF
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G5.80%3.84M shares+1.50 ppfrom 4.30%Feb 5, 20252 filingsApr 23, 2025SEC
Vanguard Group Inc13G5.60%3.73M sharesNewJul 29, 20251 filingJul 29, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on Cardiff Oncology, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CRDF
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20255:06 PM ETCommodore Capital LPand 1 other13G/A0.00%0 shares−8.10 ppfrom 8.10%Below 5%Jun 30, 2025SEC
Jul 29, 202511:26 AM ETVanguard Group Inc13G5.60%3.73M sharesNewJun 30, 2025SEC
Apr 23, 20258:19 PM ETBlackRock, Inc.13G5.80%3.84M shares+1.50 ppfrom 4.30%Mar 31, 2025SEC
Feb 12, 20252:48 PM ETPfizer Inc13G/A3.60%2.41M shares–Below 5%Dec 31, 2024SEC
Feb 5, 20255:28 PM ETBlackRock, Inc.13G/A4.30%2.84M shares–Below 5%Dec 31, 2024SEC
Dec 17, 20244:06 PM ETCommodore Capital LPand 1 other13G8.10%5.38M sharesNewDec 10, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Cardiff Oncology, Inc. shares.

No Form 144 notices for Cardiff Oncology, Inc. are on file.